Blaire L. Osborn - Concepedia

Author

Blaire L. Osborn

Human Genome Sciences (United States)

Also Known As

B OSBORN, B. L. Osborn, B. Osborn, B.L. Osborn, Blaire L Osborn, Blaire L. Osborn, Blaire Osborn

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Human Genome Sciences (United States)National Institute of Allergy and Infectious Diseases National Institutes of Health Bar-Ilan University National Cancer Institute

About

Blaire L. Osborn is an author at Human Genome Sciences (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	599
2	Natural Sciences	1	1	128
3	Biochemistry	1	1	128
4	Biomedical Engineering	1	1	128
5	Biomolecular Engineering	1	1	128

Blaire L. Osborn

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys Blaire L. Osborn, Henrik S. Olsen, Bernardetta Nardelli, Journal of Pharmacology and Experimental Therapeutics	2002	193
Albutropin: a growth hormone–albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys Blaire L. Osborn, Les Sekut, Marta L. Corcoran, European Journal of Pharmacology Molecular PharmacologyGrowth Hormone–albumin FusionGrowth HormoneHuman GrowthMedicine	2002	130
Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology Alokesh Duttaroy, Palanisamy Kanakaraj, Blaire L. Osborn, Diabetes GlycobiologyBiomedical EngineeringInsulin SignalingMetabolic SyndromeSingle-chain Human Insulin	2005	128
Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice Robert J. Melder, Blaire L. Osborn, Todd Riccobene, Cancer Immunology Immunotherapy InflammationCytokineImmunologyVivo Anti-tumor ResponseImmune Checkpoint Inhibitor	2004	111
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro Connie L. Erickson‐Miller, Richard May, Joseph E. Tomaszewski, Cancer Chemotherapy and Pharmacology MedicineStem Cell ToxicologySelective ToxicityToxicologyMyeloid Progenitors	1997	110
A Phase 1 Study of PAmAb, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers G. Mani Subramanian, P. Cronin, Gerald E. Poley, Clinical Infectious Diseases	2005	93
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients Vincent G. Bain, Kelly Kaita, Eric M. Yoshida, Journal of Hepatology HepatologyHepatitis CViral HepatitisAntiviral ActivityImmunology	2006	91
A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy Vijayan Balan, David R. Nelson, Mark Sulkowski, Antiviral Therapy	2006	68
Pharmacokinetic Data Are Predictive of <i>In Vivo</i> Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant <i>Neisseria gonorrhoeae</i> Strains in the Gonorrhea Mouse Model Kristie L. Connolly, Ann E. Eakin, Carolina Gomez, Antimicrobial Agents and Chemotherapy	2019	38
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota Barbara Lomeli, Hal Galbraith, Jared Schettler, Antimicrobial Agents and Chemotherapy	2019	35

Page 1